Sanofi (NASDAQ:SNY) Azioni

Sanofi

NYSE

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Shanghai,,China,-,June,29,,2023:,Saic,Roewe,Feifan,F7

Tech

BPMC

CRDO

PSTV

SAIC

Tra utili societari, un&#39;acquisizione miliardaria e movimenti after-hours: alcune storie pronte a sfidare il trend di mercato.

Futures in rosso: 5 titoli sotto la lente d&#39;ingrandimento oggi

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

TSVT

VRTX

L&#39;analisi sui settori più volatili e le strategie per affrontare le incertezze: ecco i trend da seguire per proteggere il tuo portafoglio.

3 titoli che potrebbero non farti dormire sonni tranquilli

Equities

Health Care

IDNA

MRNA

NVAX

Un terremoto nella sanità pubblica globale getta ombre sul futuro della lotta alle pandemie. Investitori in allerta e borse in fermento.

Scaricata l&#39;OMS in piena pandemia? Caos sanitario e mercati nel panico

Sanofi SA

Synthetify

SUNNYLIFE GLOBAL INC by Sunnylife Global, Inc.

Sunnylife Global Inc

Synergy CHC Corp

VITAL ENERGY INC (CDA) by Vital Energy, Inc.

Vital Energy Inc

SANY HEAVY EQUIP INTL HLD by Sany Heavy Equipment International Holdings Co.

Sany Heavy Equipment International Holdings Co Ltd

Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) announced results Wednesday of the initial cohort of its COVID-19-Influenza Combination (CIC) and standalone trivalent hemagglutinin nanoparticle seasonal <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">influenza (tNIV) Phase 3 trial</a>.
The study showed that the CIC and flu vaccine candidates induced immune responses similar to those of licensed comparators Nuvaxovid&nbsp;and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45879363/novavaxs-covid-19-influenza-combination-and-stand-alone-influenza-vaccine-candidates-showed-robust" rel="noreferrer noopener">Fluzone HD, respectively</a>.
Both standalone flu and CIC vaccine candidates induced robust immune responses to the vaccine strains (2.4-5.7-fold over baseline).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a>
&#8220;Both our combination and standalone flu vaccine candidates induced robust immune responses and were well tolerated,&#8221; said Ruxandra Draghia-Akli, executive vice president and head of Research and Development at Novavax.
&#8220;This&nbsp;data set adds to&nbsp;findings from our Phase 2 trial and will help inform discussions with potential partners.&#8221;
Both vaccine candidates were well tolerated and saw reactogenicity comparable to authorized comparators.
Nearly all (&gt;98%) solicited adverse events were mild or moderate in severity.&nbsp;
The cohort was designed to provide descriptive data on three flu strains&nbsp;(H1N1, H3N2, B) and SARS-CoV-2 (COVID-19) to inform a future registrational Phase 3 program.
The descriptive trial evaluated the safety and immunogenicity of the CIC and standalone flu vaccine candidates&nbsp;compared to Nuvaxovid and Fluzone HD in approximately 2,000 adults&nbsp;aged 65 and older.
This trial was not adequately powered to demonstrate statistical significance.
In May 2023, Novavax unveiled data for its COVID-influenza combination vaccine and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/05/32287464/novavax-eases-uncertainty-announces-job-cuts-encouraging-data-from-covidflu-combo-shot" rel="noreferrer noopener">two other shots</a>.
Data from a Phase 2 trial in adults aged 50-80 showed that the combination shot produced an immune response comparable to its protein-based COVID vaccine and already approved influenza shots.
The study found that all three of Novavax&#8217;s vaccine candidates—the COVID/flu combination shot, a standalone flu shot, and a higher dose of its COVID shot—were safe and well-tolerated.
In May, Novavax received limited approval from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine, Nuvaxovid. This marked a regulatory milestone and unlocking a $175 million milestone payment <a href="https://www.benzinga.com/25/05/45496095/novavax-scores-key-fda-win-shares-jump-19-as-sanofi-milestone-unlock" target="_blank" rel="noreferrer noopener">from partner Sanofi</a>.
Earlier in June, the FDA approved&nbsp;Moderna, Inc.'s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) mNexspike&nbsp;(mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease&nbsp;<a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals" rel="noreferrer noopener">Control and Prevention (CDC)</a>.
Price Action: NVAX stock is up 0.56% at $7.24 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45854247/american-pharmacists-association-withholds-endorsement-of-cdcs-revised-covid-19-vaccine-guidance" target="_blank" rel="noreferrer noopener">American Pharmacists Association Withholds Endorsement Of CDC&#8217;s Revised COVID-19 Vaccine Guidance</a></li>
</ul>
Photo: Shutterstock

Biotech

General

Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial

The American Pharmacists Association announced Monday it will withhold endorsement of the Centers for Disease Control and Prevention&#8217;s updated immunization schedule that removed COVID-19 vaccine recommendations for pregnant women and healthy children.
What Happened: The CDC modified its guidance last month, stating COVID-19 vaccines remain optional for healthy children when parents and physicians determine necessity, reported Reuters. Health Secretary Robert F. Kennedy Jr., who oversees the CDC, Food and Drug Administration and National Institutes of Health, announced the policy changes before official website updates.
&#8220;COVID-19 vaccination during pregnancy has been proven safe and effective. Additionally, this vaccine is not associated with any fertility issues in either women or men,&#8221; the pharmacists&#8217; association stated. The group emphasized that pregnancy represents a high-risk condition requiring COVID-19 vaccination recommendations.
Kennedy&#8217;s <a href="https://www.benzinga.com/government/regulations/25/05/45688464/rfk-jr-drops-covid-vaccine-recommendation-for-healthy-kids-but-experts-warn-of-major-risks">announcement bypassed the traditional CDC Advisory Committee</a> for Immunization Practices review processes. The policy shift follows FDA changes<a href="https://www.benzinga.com/news/25/05/45661031/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-children"> limiting annual boosters to Americans over 65</a> and high-risk populations while requiring new clinical trials for healthy adults under 65.
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45853504/circle-stock-has-popped-271-since-nyse-debut-now-a-kpmg-consultant-says-this-is-the-next-big-thing-after-stablecoins">Circle Stock Has Popped 271% Since NYSE Debut, Now A KPMG Consultant Says This Is The Next Big Thing After Stablecoins</a>
Why It Matters: The FDA recently advised vaccine manufacturers that fall 2025 formulations should target monovalent JN.1-lineage variants, preferentially using the LP.8.1 strain. Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) submitted its Spikevax 2025-2026 formula application targeting the LP.8.1 variant Friday.
Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) received limited FDA approval for its Nuvaxovid vaccine, authorized for individuals 65 and older and those 12 and up with underlying medical conditions. The approval triggered a $175 million milestone payment from partner Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
The policy changes create uncertainty for vaccine manufacturers and healthcare investors as the <a href="https://www.benzinga.com/government/regulations/25/05/45537919/fda-limits-annual-covid-19-boosters-to-high-risk-americans-demands-new-trials-for-healthy-adults-in-policy-shift-under-rfk-jr">administration implements stricter clinical trial</a> requirements. Previous guidance under the Biden administration recommended additional COVID-19 boosters for healthy children despite limited clinical data supporting repeat booster strategies in pediatric populations.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45853487/border-czar-tom-homan-says-no-intention-to-arrest-gavin-newsom-despite-trumps-remarks-they-havent-crossed-a-line-yet">Border Czar Tom Homan Says &#8216;No Intention&#8217; To Arrest Gavin Newsom Despite Trump&#8217;s Remarks: &#8216;They Haven&#8217;t Crossed A Line Yet&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: JHVEPhoto / Shutterstock.com

American Pharmacists Association Withholds Endorsement Of CDC's Revised COVID-19 Vaccine Guidance

French drugmaker Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">runs through March</a>.
Sanofi, in collaboration with its partner AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023.
Immunizations <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-09-05-00-00-3095598" rel="noreferrer noopener">begin</a> in early fall. The current supply for the upcoming season matches the total doses distributed last year, and production continues.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" rel="noreferrer noopener">Regeneron&#8217;s Obesity Trial With Novo Nordisk&#8217;s Wegovy Hits Lean Target</a>
Sanofi said Beyfortus duration of protection was extended for six months in the EU. This year&#8217;s EU shipments are marked by an important change to the Beyfortus EU label, extending the duration of protection through six months so Beyfortus can continue to offer season-long protection for all infants, including older babies immunized just before the RSV season begins.
More than six million babies have been immunized worldwide, and millions more will be immunized this season in more than 40 countries to help protect them from the potentially devastating impact of RSV disease.
In another development, Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi on Saturday presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent&nbsp;(dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45828306/dupixent-dupilumab-data-at-revolutionizing-atopic-dermatitis-rad-conference-reinforce-use-in-atopi" rel="noreferrer noopener">with skin of color</a>.
These are the first clinical trial results for Dupixent in a large population of patients with darker skin tones.
The results, along with the Dupixent Phase 3 trials, demonstrated patients taking Dupixent experienced improvements in signs and symptoms of atopic dermatitis from baseline across many skin tones.
The data were shared at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference. In the trial, 120 patients with atopic dermatitis and skin of color were treated with Dupixent every two weeks using a weight-based dosing regimen.
At 24 weeks:
<ul class="wp-block-list">
<li>76% achieved a ≥75% improvement in overall disease severity (EASI-75), the primary endpoint. Some patients saw improvements as early as two weeks.</li>
<li>53% achieved clinically meaningful improvement in itch (≥4-point reduction on the peak-pruritus numerical rating scale [PP-NRS]). Improvements were seen by some patients as early as two weeks.</li>
<li>Patients experienced a 53% reduction from baseline in post-inflammatory hyperpigmentation, dropping from 5.1 points (moderate/marked) to 2.4 points (mild).</li>
<li>Based on patient reporting, 18% were very or extremely bothered by dry skin, compared to 78% at baseline.</li>
<li>The safety results in the DISCOVER trial were generally consistent with the known safety profile of Dupixent in its approved dermatological indications.</li>
</ul>
Price Action: REGN stock was trading higher by 1.53% to $500.75, and SNY stock was down 0.99% at $49.97.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45817049/arcutis-unveils-long-term-efficacy-safety-for-zoryve-cream-in-pediatric-patients-with-atopic-dermatitis" target="_blank" rel="noreferrer noopener">Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis</a></li>
</ul>
Photo by HJBC via Shutterstock

Large Cap

REGN

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season

<ul>
<li>Atopic dermatitis is a chronic disease that disproportionately impacts communities of color</li>
<li>Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of treated patients</li>
<li>Patients experienced substantial reductions in hyperpigmentation, dry skin and itch from baseline</li>
<li>Results support commitment to enhance clinical understanding of chronic diseases in communities of color</li>
</ul>

Reported Saturday, Sanofi And Regeneron Present New Dupixent Results Highlighting Disease Severity Reduction In Patients With Darker Skin Tones

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Sanofi And AstraZeneca Accelerate Global Rollout Of Beyfortus To Deliver Season-Long Respiratory Syncytial Virus Protection In Over 40 Countries

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>Applied Digital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares escalated 102.93% following the announcement of a long-term <a href="https://www.benzinga.com//node/45817409" target="_blank" rel="noreferrer noopener">infrastructure agreement with</a> AI hyperscaler CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>).</li>
<li>Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) stock jumped 60.66%. The company revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class <a href="https://www.benzinga.com//node/45724030" target="_blank" rel="noreferrer noopener">oral STAT6 degrader medicine</a>. Morgan Stanley and B. Riley Securities upgraded the stock to Overweight and Buy, respectively, and the company <a href="https://www.benzinga.com/quote/kymr/analyst-ratings" target="_blank" rel="noreferrer noopener">received several price forecast bumps</a>.</li>
<li>First Majestic Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) stock increased 34.04% last week, when Silver rocketed past $35.60 an ounce Thursday, a level last seen in 2012. Gold bull Peter Schiff <a href="https://www.benzinga.com//node/45792880" target="_blank" rel="noreferrer noopener">says it's just warming up</a>.</li>
<li>AIFU Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFU#NASDAQ">AIFU</a>) shares rose 31.78%.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) shares increased 31.34% after the company announced the launch of <a href="https://www.benzinga.com//node/45814396" target="_blank" rel="noreferrer noopener">Boltz-2 in partnership with MIT</a>.</li>
<li>Cleveland-Cliffs Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) stock grew 30.36% after U.S. President Donald Trump announced <a href="https://www.benzinga.com//node/45724684" target="_blank" rel="noreferrer noopener">plans to double steel tariffs</a>.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) shares upped 26.44%. The company and NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) <a href="https://www.benzinga.com//node/45730717" target="_blank" rel="noreferrer noopener">therapy for pancreatic cancer</a>.</li>
<li>Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) stock rose 26.15% after the company announced that Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) <a href="https://www.benzinga.com//node/45719179" target="_blank" rel="noreferrer noopener">would acquire them for $9.5 billion</a>.</li>
<li>Sezzle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) stock escalated 23.78% last week.</li>
<li>Riot Platforms, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) stock rose 22.06%. The company mined 514 bitcoin in May, up 11% month over month and <a href="https://www.benzinga.com//node/45752589" target="_blank" rel="noreferrer noopener">139% year over year</a>.</li>
</ol>
Photo by T. Schneider via Shutterstock

Mid Cap

Movers

AIFU

APLD

CRWV

KYMR

NVCR

RIOT

RXRX

SEZL

ZLAB

Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?

<h3 class="wp-block-heading">New On The Block</h3>
Byron Allen's Allen Media Group has hired Moelis &amp; Company to explore a sale of its TV stations across 21 markets. The company spent over $1 billion acquiring Big Four network affiliates (ABC, NBC, CBS, FOX) over the past six years. 
It is now looking to cash out and reduce debt. Deadline <a href="https://deadline.com/2025/06/allen-media-group-hires-investment-bank-to-sell-tv-stations-1236420381/">reported</a> that the TV stations have received multiple offers. 
Also for sale: 
<ul class="wp-block-list">
<li>Jefferies is shopping around PatientPoint, a health marketing and ad agency, according <a href="https://www.axios.com/pro/health-tech-deals/2025/06/04/patientpoint-jefferies-sale">to</a> Axios. L Catterton, Littlejohn &amp; Co. and Transformation Capital are on the sell side. </li>
<li>Just three years ago, private equity firm One Equity Partners <a href="https://www.oneequity.com/news/one-equity-partners-completes-investment-in-infucare-rx-a-leading-home-infusion-therapy-provider/">completed</a> a strategic investment in infusion provider InfuCare. Today? It&#8217;s looking to get rid of it. According to Axios, JPMorgan is <a href="https://www.axios.com/pro/health-tech-deals/2025/06/03/infucare-one-equity-jpmorgan-sale">looking</a> for a buyer. </li>
<li>Swiss biotech MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) received a <a href="https://www.benzinga.com/news/health-care/25/06/45743008/mercks-dealmaking-intensifies-with-moonlake-bid-as-keytruda-patent-cliff-nears-report">bid exceeding $3 billion</a> from Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>). MoonLake turned down the initial offer, but talks are reportedly revived. The potential purchase signals renewed dealmaking activity as investor pressure has mounted on Merck to secure new assets, especially as its blockbuster <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">cancer drug Keytruda</a> faces patent expiration as early as 2028.</li>
</ul>
<h3 class="wp-block-heading">Updates From The Block</h3>
<ul class="wp-block-list">
<li>Post Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>) is forking over $880 million—including assumed debt—to buy 8th Avenue Food &amp; Provisions. That means brands like Ronzoni pasta will go back into Post&#8217;s pantry. <a href="https://www.wsj.com/articles/post-holdings-to-buy-ronzoni-pasta-owner-8th-avenue-food-cf8f454c?mod=deals_news_article_pos2">Per</a> The Wall Street Journal, the private-label brands originally got spun off into 8th Avenue in 2018 with help from private equity firm THL. Post plans to wipe out 8th Avenue's net debt and pick up the tab for all equity interests, including $111 million in finance leases. All in, the transaction is expected to cook up $15 million in annual synergies by the end of fiscal 2026. If Post closes by July 1, it expects 2026 to be more profitable (on an adjusted basis) than initially expected.</li>
</ul>
<ul class="wp-block-list">
<li>Rosebank Industries (LON: ROSE) is once again in talks to buy Electrical Components International (ECI), a wire harnesses manufacturer, for about $1.9 billion, Reuters reported. Rosebank was in talks to buy ECI in February but dropped the plans in March.</li>
</ul>
<ul class="wp-block-list">
<li>Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) agreed to acquire Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU. The acquisition will also include elenestinib, a next-generation medicine for SM, and BLU-808, a highly selective and potent oral wild-type KIT inhibitor with the potential for immunology diseases. Sanofi will pay&nbsp;$129&nbsp;per share in cash, representing an equity value <a href="https://www.benzinga.com/news/health-care/25/06/45719179/sanofi-expands-rare-immunology-portfolio-with-blueprint-buyout">of roughly&nbsp;$9.1 billion</a>.</li>
</ul>
<ul class="wp-block-list">
<li>Suzano S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">SUZ</a>) is acquiring a 51% stake in a new $3.4 billion tissue products joint venture with Kimberly-Clark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NASDAQ">KMB</a>), <a href="https://www.benzinga.com/m-a/25/06/45797473/tissue-titans-unite-suzano-kimberly-clark-form-3-4-billion-global-jv">paying $1.734 billion in cash</a>. Kimberly-Clark will retain a 49% stake. The Netherlands-based venture will produce and distribute toilet paper and facial tissues in 70 countries, with 22 factories across 14 countries, employing about 9,000 people. The facilities have an annual capacity of 1 million tonnes and generated $3.3 billion in net sales in 2024.</li>
</ul>
<h3 class="wp-block-heading">Off The Block</h3>
<ul class="wp-block-list">
<li>Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45740112/robinhood-completes-200-million-bitstamp-deal-gains-access-to-500k-crypto-users-and-95-million-revenue-stream">completed its $200 million acquisition</a> of Bitstamp, a crypto exchange that had raised around $40 million from firms like Pantera Capital and Ripple.</li>
</ul>
<ul class="wp-block-list">
<li>Cactus Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) <a href="https://www.benzinga.com/m-a/25/06/45724879/cactus-takes-majority-stake-in-baker-hughes-spc-for-global-reach">formed a joint venture</a> with Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), taking a 65% stake and operational control of Baker Hughes&#8217; Surface Pressure Control (SPC) business. Baker Hughes will retain a 35% stake. The new venture, separate from Cactus' current pressure control unit, will focus on international wellhead and production tree systems.</li>
</ul>
<ul class="wp-block-list">
<li>Guardian Pharmacy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) is <a href="https://www.benzinga.com/pressreleases/25/06/b45719054/guardian-pharmacy-services-expands-pacific-northwest-footprint-with-acquisition-of-washington-base" target="_blank" rel="noreferrer noopener">entering the Pacific Northwest market</a> via acquisition. Mercury Pharmacy Services, a provider of long-term care pharmacy solutions, agreed to a price, but <a href="https://www.benzinga.com/m-a/25/06/45723960/guardian-pharmacy-strengthens-us-footprint-with-new-seattle-area-acquisition">the amount remains undisclosed</a>.</li>
</ul>
<h3 class="wp-block-heading">Bankruptcy Block</h3>
<ul class="wp-block-list">
<li>AI startup Builder.ai has filed for Chapter 7 bankruptcy in Delaware after creditors seized most of its cash, citing overstated 2024 sales projections—by a staggering 300%. Once valued at $1.5 billion, Builder.ai is now the biggest AI collapse since the ChatGPT-driven investment boom began. According <a href="https://www.bloomberg.com/news/articles/2025-06-05/builder-ai-files-for-bankruptcy-after-creditors-seize-accounts?sref=TBDibEcD">to</a> Bloomberg, the fallout was fueled by revelations that Builder.ai allegedly faked business with Indian social media firm VerSe Innovation to inflate revenues. VerSe co-founder Umang Bedi denies any wrongdoing, calling the claims "baseless and false."</li>
</ul>
<ul class="wp-block-list">
<li>Hooters closed some 30 corporate-owned restaurants and explained that it has <a href="https://www.businesswire.com/news/home/20250331979797/en/Hooters-of-America-Takes-Strategic-Action-to-Continue-its-Iconic-Legacy-Under-Pure-Franchise-Business-Model" target="_blank" rel="noreferrer noopener">no plans </a>to shut down any other locations. The Atlanta, Georgia-based restaurant chain went <a href="https://www.benzinga.com/personal-finance/25/04/44647084/hooters-files-for-bankruptcy-says-brand-isnt-going-anywhere">bankrupt earlier this year</a>.</li>
</ul>
<ul class="wp-block-list">
<li>Alex Jones may see his personal assets — including guns, cars, and homes — sold by the end of the year, according to the Houston Chronicle, <a href="https://www.houstonchronicle.com/news/houston-texas/texas/article/alex-jones-personal-assets-sales-bankruptcy-20361565.php">citing</a> a bankruptcy trustee. The potential sale would mark the nearing end of his two-and-a-half-year bankruptcy process. Jones, who created the far-right conspiracy theory website Infowars, filed for bankruptcy in 2022 after being ordered to pay nearly $1.5 billion to families of Sandy Hook shooting victims for defamation.</li>
</ul>
<h3 class="wp-block-heading">Notes From The Block</h3>
A studio's IP portfolio and game development pipeline are critical for video game investors. A major acquirer in the sector is GDEV Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEV#NASDAQ">GDEV</a>). The Cyprus-based company has made three M&amp;A deals and spent $100 million on studio acquisitions since 2022. 
This week, Andrey Fadeev drafted <a href="https://www.benzinga.com/m-a/25/06/45722621/gdevs-founder-ceo-evaluates-m-a-deals-using-these-5-metrics">a listicle of key metrics</a> GDEV uses for M&amp;A evaluation.
<ol class="wp-block-list">
<li>LTV/CAC Ratio – Measures how efficiently a studio converts user acquisition spend into revenue. A ratio above 1.0 indicates profitable user growth.</li>
<li>Retention Rates (D1, D7, D30) – Track user engagement over time. High retention signals strong gameplay and monetization potential. Benchmarks vary by genre.</li>
<li>ARPU/ARPPU – Indicate monetization efficiency. ARPU includes all users; ARPPU focuses on paying users. Higher ARPU justifies higher CAC.</li>
<li>DAU/MAU Ratio – Shows user engagement depth. A ratio above 20% is considered strong.</li>
<li>EBITDA – Reflects core operational profitability and financial health. High EBITDA margins show sustainable growth and efficiency.</li>
</ol>
In 2024, video game M&amp;A activity reached $27.3 billion, underscoring the sector's immense growth and investment appeal. C-suite executives would be wise to consider these metrics when searching for their next target. 
<a href="https://www.benzinga.com/markets/asset-sales/25/05/45702349/deal-dispatch-beauty-brand-behavioral-health-firms-hit-auction-block">For last week&#8217;s edition of Deal Dispatch, click here</a>.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/45816311/conagra-sells-seafood-brands-for-55m-as-it-sharpens-focus-on-core-business">Conagra Sells Seafood Brands For $55M As It Sharpens Focus On Core Business</a></li>
</ul>
Image created using a photo from Shutterstock.

Asset Sales

GDEV

GRDN

HOOD

KEYS

MLTX

POST

ROSE

SNOW

Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta

U.S. Health Secretary Robert F. Kennedy Jr. has championed &#8220;medical freedom&#8221; while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health experts call a dichotomy in his approach to healthcare policy.
What Happened: Kennedy announced last week that the Centers for Disease Control and Prevention would remove COVID-19 vaccines from <a href="https://www.benzinga.com/news/25/05/45661031/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-children">recommended </a>immunization schedules for healthy children and pregnant women.
The decision bypassed traditional advisory committee processes and shifted coverage from routine recommendations to shared clinical decision-making between doctors and patients.
&#8220;Regarding the vaccines, HHS is restoring the doctor-patient relationship,&#8221; HHS spokesperson Andrew Nixon said in a <a href="https://abcnews.go.com/Health/rfk-jr-promoted-freedom-choice-limiting-vaccines-food/story?id=122526364">statement</a> to ABC News. &#8220;We are encouraging those groups to consult with their health care provider to help them make an informed decision.&#8221;
Kennedy has also pushed to ban Supplemental Nutrition Assistance Program recipients from purchasing candy and soda with food stamps. Ten state governors have submitted waivers to the Agriculture Department requesting permission for such restrictions, according to Kennedy&#8217;s statements at a Make America Healthy Again event in May.
The Food and Drug Administration began <a href="https://www.benzinga.com/government/regulations/25/05/45399804/robert-kennedy-jr-cheers-fda-plan-to-ban-fluoride-supplements-for-children-calls-move-long-overdue">removing fluoride supplements for children </a>from the market, earning Kennedy&#8217;s praise as &#8220;long overdue.&#8221; The agency cited a lack of FDA approval and evidence that these products alter gut microbiomes.
Kennedy&#8217;s broader MAHA initiative has influenced restaurant chains to eliminate seed oils. Biglari Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BH#NYSE">BH</a>) subsidiary Steak &#8216;n Shake switched to beef tallow for French fries, while Sweetgreen Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>), Bloomin&#8217; Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>), and Restaurant Brands International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) have initiated similar transitions.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45809455/tesla-stock-climbed-nearly-5-in-friday-pre-market-whats-going-on">Tesla Stock Climbed Nearly 5% In Friday Pre-Market: What&#8217;s Going On?</a>
Why It Matters: Critics argue Kennedy&#8217;s policies contradict his &#8220;medical freedom&#8221; messaging by limiting choices. Removing COVID vaccines from CDC schedules restricts access while claiming to promote freedom.
&#8220;If you restrict access, you necessarily restrict choice,&#8221; Dr. Matthew Ferrari of Pennsylvania State University told ABC News. Public health experts warn Kennedy&#8217;s approach individualizes community health decisions. &#8220;We&#8217;re losing a lot of that underpinning, which has led to a lot of the gains in public health,&#8221; Dr. Craig Spencer of Brown University told ABC News.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45809443/larry-summers-identifies-3-key-reasons-for-rising-us-debt-but-doesnt-think-trumps-big-beautiful-bill-is-the-medicine-the-country-needs">Larry Summers Identifies 3 Key Reasons For Rising US Debt, But Doesn&#8217;t Think Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Is The Medicine The Country Needs</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

BLMN

RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Experts

<a href="https://www.statnews.com/2025/06/05/glp-1-drugs-low-but-elevated-risk-of-age-related-macular-degeneration/?utm_campaign=rss" title="https://www.statnews.com/2025/06/05/glp-1-drugs-low-but-elevated-risk-of-age-related-macular-degeneration/?utm_campaign=rss">https://www.statnews.com/2025/06/05/glp-1-drugs-low-but-elevated-risk-of-age-related-macular-degeneration/?utm_campaign=rss</a>

'GLP-1 Drugs May Be Linked To Elevated Risk Of Serious Eye Disease, Study Finds' - STAT News

Sanofi Launches 2025 Global Employee Stock Purchase Plan Offering Shares At €72.97 With 20% Discount And Matching Incentive

<a href="https://www.dailymail.co.uk/health/article-14773791/ozempic-weight-loss-drugs-kidney-cancer-risk-study.html" title="https://www.dailymail.co.uk/health/article-14773791/ozempic-weight-loss-drugs-kidney-cancer-risk-study.html">https://www.dailymail.co.uk/health/article-14773791/ozempic-weight-loss-drugs-kidney-cancer-risk-study.html</a>

"Exclusive: Ozempic Linked To 'Silent Cancer' That Is Rising In Young People As Doctors Issue Shock Warning" - DailyMail+

ASCO: new Sarclisa data support subcutaneous administration with on-body injector
<ul>
<li>New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusion</li>
<li>Studies used Enable Injections' enFuse&#xAE; on-body injector, an automated hands-free injector</li>
<li>Data will form the basis of global regulatory submissions across all currently approved lines of treatment &nbsp;</li>
</ul>
Paris, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa's efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the <a href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-01-09-06-00-00-3006798">IRAKLIA phase 3 study</a>, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.

Sanofi Announces New Data Shows Subcutaneous Sarclisa Delivered Via On-Body Injector Cuts Treatment Time To Minutes While Maintaining Efficacy And Safety, At ASCO 2025

Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
<ul>
<li>Fourth orphan drug designation for rilzabrutinib in rare diseases</li>
<li>Under regulatory review in the US, the EU, and China in immune thrombocytopenia</li>
</ul>

Sanofi's Rilzabrutinib Receives Fourth Orphan Drug Designation In The US, Targeting Vaso-Occlusive Crises In Sickle Cell Disease

Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">STAT6 degrader medicine</a>.
The findings significantly surpassed the company&#8217;s expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release.
Pharmacokinetics (PK):
KT-621 demonstrated a favorable <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45717730/kymera-therapeutics-announces-positive-first-in-human-results-from-phase-1-healthy-volunteer-clini" rel="noreferrer noopener">plasma PK profile</a> after single and multiple doses. Rapid absorption was demonstrated with a median tmax&nbsp;of 2-4 hours and a mean half-life of 9-36 hours. There was a dose-proportional increase in exposure after multi-dosing, and a steady state was achieved by Day 4.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals" rel="noreferrer noopener">Moderna&#8217;s New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals</a>
Pharmacodynamics (PD):
KT-621 demonstrated rapid, deep, and prolonged STAT6 degradation in blood after single doses of KT-621 and in blood and skin after multiple doses of KT-621.
STAT6 levels in blood and skin were measured. Complete degradation within a cohort is defined as either a mean reduction of ≥95% or, when most subjects&#8217; STAT6 levels are reduced below the Lower Limit of Quantification (LLOQ), or both.
In SAD, maximal degradation was achieved in blood as quickly as the first collected timepoint of 4 hours after a single dose, with mean STAT6 degradation reaching &gt;90% across all SAD doses starting at 6.25 mg.
All SAD cohorts at 75 mg or greater doses achieved &gt;95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects.
In MAD, STAT6 degradation was observed in blood at the first timepoint measured (8 hours) for doses above 1.5 mg.
Steady-state, complete degradation, associated with STAT6 reductions below the LLOQ in the majority of subjects, was achieved at doses ≥50 mg, with recovery starting as early as 4 days after the last dose.
In MAD, robust STAT6 degradation was observed in the skin at the first timepoint measured (Day 7) for doses above 1.5 mg.
Steady-state, complete degradation, associated with ≥95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects, was achieved at doses ≥50 mg.
Th2 Biomarkers:
TARC reduction was observed for all KT-621 dose groups, with a median reduction of up to 37% at Day 14.
The company says the results are comparable or superior to what was seen in the Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)/Regeneron Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Dupixent (dupilumab) healthy volunteer study.
The safety profile of KT-621 was undifferentiated from that of the placebo.
The company&#8217;s KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis patients is ongoing, with data expected to be reported in the fourth quarter of 2025. 
Two parallel Phase 2b trials in atopic dermatitis and asthma will start in 4Q25 and 1Q26, respectively.
Price Action: KYMR stock was trading higher by 30.2% to $38.58 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45720783/kidney-health-focused-vera-therapeutics-stock-price-spikes-on-heels-of-successful-trial-data" target="_blank" rel="noreferrer noopener">Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data</a></li>
</ul>
Photo via Shutterstock

Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response

The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) mNexspike&nbsp;(mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Control and Prevention (CDC)</a>.
&#8220;The FDA approval of our third product, mNEXSPIKE&#8230;,&#8221; said Stéphane Bancel, Chief <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/ac45708511/moderna-receives-u-s-fda-approval-for-covid-19-vaccine-mnexspike" rel="noreferrer noopener">Executive Officer of Moderna</a>.
The FDA&#8217;s approval of mNEXSPIKE is based on results from a randomized, observer-blind, active-controlled Phase 3 trial, which enrolled approximately 11,400 participants aged 12 years and older.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a>
The primary efficacy objective was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNexspike compared to that after the comparator vaccine, mRNA-1273 (Spikevax), Moderna&#8217;s original COVID-19 vaccine.
Participants received either a 10 μg dose of mRNA-1283 or a 50 μg dose of mRNA-1273.
mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older.
In the Phase 3 trial, mRNA-1283 was found to have a similar safety profile to mRNA-1273, with fewer local reactions and comparable systemic reactions.
The most commonly solicited side effects were injection site pain, fatigue, headache and myalgia.
Moderna expects to have mNexspike available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA, the company&#8217;s approved respiratory syncytial virus (RSV) vaccine.
William Blair writes, &#8220;Approval of mRNA-1283 is an incremental win for Moderna, especially considering HHS Secretary Robert F. Kennedy Jr.&#8217;s negative public opinion on mRNA COVID-19 vaccines, and we continue to see autonomy and data-driven decisions at the FDA.&#8221;
&#8220;We do not see approval of mRNA-1283 as a massive boost to Moderna&#8217;s COVID-19 vaccine sales, which we believe are primarily driven by sentiment surrounding the vaccination market in general, but this is a critical step in the regulatory path for the combo flu/COVID vaccine product, mRNA-1083, which uses mRNA-1283 as the COVID-19 component of its formulation,&#8221; analyst Myles Minter writes.
Analyst Minter says Moderna is still facing challenges from new government policies, including <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45663794/hhs-cancels-590m-moderna-bird-flu-vaccine-deal-casting-uncertainty-over-pandemic-preparedness-effort" rel="noreferrer noopener">losing about $700 million</a> in funding from the Department of Health and Human Services for its bird flu vaccine project.
In addition, William Blair writes that the company&#8217;s goal to break even by 2028 is overly optimistic since it would need to more than double its revenue—based on cash costs—to reach that target.
In May, the FDA approved Novavax, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) Nuvaxovid for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years and older and individuals 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19 (e.g. asthma, cancer, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45489838/u-s-fda-approves-bla-for-novavaxs-covid-19-vaccine" rel="noreferrer noopener">diabetes, obesity, smoking)</a>.
Achievement of the U.S. license approval has triggered a&nbsp;$175 million&nbsp;milestone payment from Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
Price Action: MRNA stock is up 4.82% at $27.84 during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/05/45703385/dell-wins-wall-street-praise-after-12-billion-ai-server-orders-solid-commercial-pc-demand" target="_blank" rel="noreferrer noopener">Dell Wins Wall Street Praise After $12 Billion AI Server Orders, Solid Commercial PC Demand</a></li>
</ul>
Photo by Wolfilser via Shutterstock

Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals

Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>).
The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">early-stage immunology pipeline</a>.
Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM &amp; ISM), a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs.
The acquisition will also include elenestinib, a next-generation medicine for SM, and BLU-808, a highly selective and potent oral wild-type KIT inhibitor with the potential for immunology diseases.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/41987123/blood-cancer-focused-blueprint-medicines-could-be-attractive-target-for-partnerships-analyst-initiates-with-around-30-upside" rel="noreferrer noopener">Blood Cancer-Focused Blueprint Medicines Could Be &#8216;Attractive Target For Partnerships&#8217;: Analyst</a>
Sanofi will pay&nbsp;$129.00&nbsp;per share in cash, representing an equity value of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45714358/sanofi-to-acquire-blueprint-medicines-expanding-portfolio-in-rare-immunological-disease-and-adding" rel="noreferrer noopener">approximately&nbsp;$9.1 billion</a>.
Blueprint shareholders will also receive one contingent value right (CVR), which entitles the holder to two potential milestone payments of&nbsp;$2&nbsp;and&nbsp;$4&nbsp;per CVR to achieve future development and regulatory milestones for BLU-808.
The total equity value of the transaction, including potential CVR payments, represents approximately&nbsp;$9.5 billion&nbsp;on a fully diluted basis.
Paul Hudson, CEO of Sanofi, said, &#8220;The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios&#8230;It complements recent acquisitions of early-stage medicines that remain our main field of interest. Sanofi still retains a sizeable capacity for further acquisitions.&#8221;&nbsp;
Ayvakit achieved net revenues of&nbsp;$479 million&nbsp;in 2024 and nearly&nbsp;$150 million&nbsp;in Q1 2025, representing year-on-year growth of more than 60% over Q1 2024.
Sanofi currently expects to complete the acquisition in the third quarter of 2025. The acquisition will not significantly impact Sanofi&#8217;s financial guidance for 2025. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026.
In another development, Sanofi exercised its option to exclusively license Nurix Therapeutics, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) STAT6 program on Monday, including the drug development candidate NX-3911, an oral, highly selective STAT6 degrader.
STAT6 (signal transducer and activator of transcription 6) plays a central role in type 2 inflammation, which drives diseases such as atopic dermatitis and asthma.
Under its 2019 collaboration agreement, Nurix will receive a $15 million license extension fee from Sanofi, bringing the total amount received under this <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45717764/sanofi-exercises-license-extension-option-to-nurixs-stat6-program" rel="noreferrer noopener">collaboration to $127 million</a>.
Nurix is eligible for an additional $465 million in development, regulatory, and commercial milestones associated with the STAT6 program and potential future royalties and retains an option to co-develop and co-promote in the U.S.
Price Action: SNY stock is trading lower by 0.73% to $49.01, BPMC stock is trading higher by 26.8% to $128.50, and NRIX stock is trading lower by 0.28% to $10.60 during the premarket session at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45703311/us-listed-chinese-stocks-drop-after-trump-renews-trade-tensions" target="_blank" rel="noreferrer noopener">US Listed Chinese Stocks Drop After Trump Renews Trade Tensions</a></li>
</ul>
Photo by HJBC via Shutterstock

Contracts

NRIX

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

Shares of Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) rose sharply in <a href="https://www.benzinga.com/quote/BPMC/news">today's pre-market trading</a>.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced plans to acquire Blueprint Medicines for $9.5 billion.
Blueprint Medicines shares jumped 26.9% to $128.62 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares jumped 199% to $14.74 in pre-market trading after the company reported positive results from the ENLIGHTEN 2 Phase 3 trial of LYR-210 achieving statistically significant results for primary and key secondary endpoints in the treatment of Chronic Rhinosinusitis (CRS).</li>
<li>InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) rose 93.2% to $4.81 in pre-market trading.</li>
<li>Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) surged 69% to $32.02 in pre-market trading after the company said Atacicept ORIGIN Phase 3 trial met primary endpoint of reduction in UPCR for IgAN treatment.</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) jumped 68.5% to $0.47 in pre-market trading after gaining 13% on Friday.</li>
<li>Basel Medical Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) surged 51.4% to $9.20 in pre-market trading after jumping 485% on Friday.</li>
<li>Black Spade Acquisition II Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSII#NASDAQ">BSII</a>) gained 37.3% to $13.29 in pre-market trading after falling 5% on Friday.</li>
<li>DigiAsia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) climbed 27.7% to $1.6990 in pre-market trading after jumping 24% on Friday.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) rose 25.6% to $7.32 in pre-market trading.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) gained 14.1% to $109.32 in pre-market trading. BioNTech and Bristol Myers Squibb announced a global strategic partnership to co-develop and co-commercialize next-generation bispecific antibody candidate BNT327 broadly for multiple solid tumor types</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares dipped 23.2% to $3.77 in pre-market trading. ReShape Lifesciences entered into equity distribution agreement relating to sale of up to $9.7 million of shares of common stock.</li>
<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares fell 22.6% to $0.7500 in pre-market trading after the company announced suspension of Nasdaq trading.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) fell 20.2% to $0.8300 in pre-market trading after gaining 8% on Friday.</li>
<li>SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) declined 18.4% to $62.60 in pre-market trading after the company filed for mixed shelf offering.</li>
<li>ContextLogic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) shares tumbled 18.3% to $6.70 in pre-market trading. ContextLogic will commence trading on the OTC Markets and delist from the Nasdaq.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) fell 17.9% to $0.8788 in pre-market trading after the company announced a proposed public offering.</li>
<li>Super League Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) fell 16.4% to $0.1629 in today's pre-market trading. Super League Enterprise, on Friday, announced a registered direct offering.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) dipped 16% to $1.68 in pre-market trading. TIAN RUIXIANG shares gained 8% on Friday after the company announced plans to buy Ucare for $150 million in an all-stock deal.</li>
<li>Lucid Diagnostics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) shares fell 15.1% to $1.18 in pre-market trading. Lucid Diagnostics may offer sell shares of common stock of up to $25 MILLION.</li>
<li>Algoma Steel Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) fell 9.2% to $4.78 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

ASTL

BMGL

BNAI

BNTX

BSII

CLEU

FAAS

LOGC

LUCD

LYRA

RSLS

SBET

SLXN

TIRX

VERA

Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket

<ul>
<li>STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions</li>
<li>Nurix to receive a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix under this collaboration to date to $127 million</li>
<li>Nurix is eligible for an additional $465 million in development, regulatory and commercial milestones associated with the STAT6 program as well as potential future royalties and retains an option to co-develop and co-promote in the U.S.</li>
</ul>

Sanofi Has Exercised Its Option To Exclusively License Nurix Therapeutics' STAT6 Program, Including The Drug Development Candidate NX-3911, Nurix To Receive A $15M License Extension Fee From Sanofi Under Its 2019 Collaboration Agreement

U.S. stock futures fell on Monday after a mixed close on Friday. Futures of major benchmark indices were trading lower in premarket.
After the Federal appeals court temporarily reinstated Donald Trump&#8216;s tariffs, he accused <a href="https://www.benzinga.com/news/legal/25/05/45683326/trump-tariffs-temporarily-preserved-as-appeals-court-pauses-lower-ruling">China of violating an agreement</a> with the U.S. to ease tariffs in his Truth Social <a href="https://truthsocial.com/@realDonaldTrump/posts/114596705340367716">post</a>. 
However, Trump did not specify the details of this violation. Treasury Secretary Scott Bessent on Sunday clarified that China was withholding critical minerals it agreed to release in a trade deal the country signed with U.S. negotiators last month in Geneva.
Meanwhile, the 10-year Treasury bond yielded 4.44% and the two-year bond was at 3.92%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 98.7% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.48%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.53%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.68%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.58%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Monday. The SPY was down 0.53% at $586.24, while the QQQ declined 0.63% to $515.83, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Sectoral moves led the U.S. stocks to a mixed close on Friday, with energy, consumer discretionary, and information technology stocks posting the largest declines, while consumer staples and utilities ended higher.
Wall Street ended May on a strong note, with the S&amp;P 500 up 6.2% and the Nasdaq soaring 9.6%, marking their best months since November 2023. The Dow gained 3.9% for the month.
Weekly gains showed the S&amp;P 500 advancing, the Dow up 1.6%, and the tech-heavy Nasdaq rising 2%.
Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) shares dropped over 2% after mixed first-quarter results, while Ulta Beauty Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) surged about 12% on better-than-expected Q1 earnings and raised guidance.
Economic data revealed the University of Michigan consumer sentiment revised up to 52.2 in May from a preliminary 50.8, while the Chicago PMI fell to 40.5 from 44.6 in the prior month.
The Dow Jones index ended 54 points or 0.13% higher at 42,270.07, whereas the S&amp;P 500 index fell 0.0081% to 5,911.69. Nasdaq Composite declined 0.28% to 19,113.77, and the small-cap gauge, Russell 2000, tumbled 0.41% to 2,066.29.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.28%</td>
<td>19,113.77</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.0081%</td>
<td>5,911.69</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.13%</td>
<td>42,270.07</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.41%</td>
<td>2,066.29</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
According to Bob Elliott, the CIO of Unlimited Funds, there was a "consensus" among the market participants that TACO trade or Trump Always Chickens Out' trade is priced in, meaning investors anticipate Trump's tariff retreats, especially now that he is embroiled in the legal battle over the validation of his levied tariffs.
He implied that TACO could pave the way for a "Run It Hot" economic environment, characterized by growth-oriented policies and sustained stimulus, further fueling market optimism.
Elliott's post signaled a widespread belief that Trump&#8217;s possible tariff rollbacks or extensions are not only predictable but also conducive to a pro-growth economic stance.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">TACO and Run It Hot are consensus at this point.
&mdash; Bob Elliott (@BobEUnlimited) <a href="https://twitter.com/BobEUnlimited/status/1929147958139744440?ref_src=twsrc%5Etfw">June 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, head of research at Fundstrat Global Advisors, Tom Lee, stated that a "<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45715677/tom-lee-bets-on-a-new-bull-market-as-trumps-tariff-retreat-fuels-taco-trade-a">new bull market</a>" has emerged following the spike in the volatility gauge in April. &#8211;
"I think we had what was a miniature bear market, but has essentially rebirthed the new bull market," he <a href="https://www.cnbc.com/2025/05/30/tom-lee-says-the-april-selloff-rebirthed-a-new-bull-market-.html?__source=twitter%7Cpro&amp;taid=6839dcb51dc732000173796f&amp;utm_campaign=trueanthem&amp;utm_content=pro&amp;utm_medium=social&amp;utm_source=twitter">told</a> CNBC as he expects "pretty shallow" dips from here, advising investors to consider small-cap stocks other than the Magnificent 7
"As I look at the second half, I think the small caps really have a strong case to be made, because as long as we move towards a tariff resolution, or the markets feel that way, then I think investors can actually start putting flows back into stocks other than the Mag Seven,&#8221; Lee said.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on this week:
<ul class="wp-block-list">
<li>On Monday, May&#8217;s S&amp;P final U.S. manufacturing PMI will be released by 9:45 a.m. ET.</li>
<li>ISM manufacturing data for May and construction spending data for April will be out by 10:00 a.m. ET.</li>
<li>Dallas Fed President Lorie Logan will speak at 10:15 a.m., Chicago Fed President Austan Goolsbee will speak at 12:45 p.m., and Federal Reserve Chair Jerome Powell will speak at 1:00 p.m. ET.</li>
<li>Auto sales data will also be released on Monday.</li>
<li>On Tuesday, April&#8217;s factory orders and job openings data will be out by 10:00 a.m. ET.</li>
<li>Chicago Fed President Austan Goolsbee will speak at 12:45 p.m., Federal Reserve Governor Lisa Cook will speak at 1:00 p.m., and Dallas Fed President Lorie Logan will speak at 3:30 p.m. ET.</li>
<li>On Wednesday, May&#8217;s ADP employment data will be out by 8:15 a.m. ET.</li>
<li>May&#8217;s S&amp;P final U.S. services PMI will be released at 9:45 a.m., and ISM services data will be out by 10:00 a.m. ET.</li>
<li>Atlanta Fed President Raphael Bostic and Federal Reserve Governor Lisa Cook will speak at the Fed listens event at 10:15 a.m. ET.</li>
<li>Fed Beige Book will be out by 2:00 p.m. ET.</li>
<li>On Thursday, the initial jobless claims data for the week ended May 31, April U.S. trade deficit, and first quarter&#8217;s U.S. productivity data will be out by 8:30 a.m. ET.</li>
<li>Federal Reserve Governor Adriana Kugler will speak at noon, and Philadelphia Fed President Patrick Harker will speak at 1:30 p.m. ET.</li>
<li>On Friday, May&#8217;s U.S. employment report, unemployment rate, and hourly wages data will be released by 8:30 a.m. ET.</li>
<li>April&#8217;s consumer credit data will be announced at 3:00 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Campbell&#8217;s Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) rose 2.32% in premarket on Monday as analysts expect it to report quarterly earnings of 66 cents per share on revenue of $2.43 billion, before the opening bell.</li>
<li>Science Applications International Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) was up 0.29% ahead of its earnings, which are supposed to be released before the opening bell. Analysts expect earnings of $2.13 per share on revenue of $1.87 billion.</li>
<li>Credo Technology Group Holding Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) declined 1.03% as analysts expect it to report quarterly earnings of 28 cents per share on revenue of $160.16 million, after the closing bell.</li>
<li>Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) advanced 0.32% after it announced plans to acquire Blueprint Medicines Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), which jumped 26.78%, for $9.5 billion.</li>
<li>Brand Engagement Network Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) surged 63.73% after its plans to acquire Cataneo GmbH for $19.5 million were extended, with $550,000 paid so far.</li>
<li>Plus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) gained 37.05% after its cancer drug REYOBIQ extended patient survival to 17 months.</li>
<li>Ryvyl Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) climbed 26.19% after it received an extension from Nasdaq to regain compliance with listing requirements after failing to meet minimum stockholders&#8217; equity criteria last week.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 3.55% to hover around $62.95 per barrel.
Gold Spot US Dollar rose 1.78% to hover around $3,348.94 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.64% at the 98.6940 level.
Asian markets closed lower on Friday except South Korea's Kospi index. Australia's ASX 200, China&#8217;s CSI 300, India's S&amp;P BSE Sensex, Japan's Nikkei 225, and Hong Kong's Hang Seng indices declined. European markets were lower in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45715677/tom-lee-bets-on-a-new-bull-market-as-trumps-tariff-retreat-fuels-taco-trade-amid-run-it-hot-optimism">Tom Lee Bets On &#8216;A New Bull Market,&#8217; As Trump&#8217;s Tariff Retreat Fuels &#8216;TACO&#8217; Trade Amid &#8216;Run It Hot&#8217; Optimism </a></li>
</ul>
Photo courtesy: godongphoto / Shutterstock.com

DELL

RVYL

ULTA

US Stocks Likely To Open Lower After A Solid May: 'TACO' Trade And 'Run It Hot' Optimism 'Are Consensus At This Point,' Says Expert

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul class="wp-block-list">
<li>Wall Street expects Campbell&#8217;s Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) to report quarterly earnings at 66 cents per share on revenue of $2.43 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Campbell&#8217;s shares gained 0.6% to $34.24 in after-hours trading.</li>
<li>Analysts expect Science Applications International Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) to post quarterly earnings at $2.13 per share on revenue of $1.87 billion. The company will release earnings before the markets open. SAIC shares rose 0.2% to $115.71 in after-hours trading.</li>
<li>Plus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) posted a net loss of $17.4 million, or $1.19 per share, for the first quarter, versus a year-ago net loss of $3.3 million, or 75 cents per share. Plus Therapeutics shares jumped 34.2% to $0.3851 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul class="wp-block-list">
<li>Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced plans to acquire Blueprint Medicines Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) for $9.5 billion. Blueprint Medicines shares fell 1.7% to close at $101.35 on Friday.</li>
<li>Analysts expect Credo Technology Group Holding Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) to post quarterly earnings at 28 cents per share on revenue of $160.16 million after the closing bell. Credo Technology shares gained 0.6% to $61.30 in after-hours trading.</li>
</ul>
Check This Out:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8"> Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Campbell's, SAIC And 3 Stocks To Watch Heading Into Monday

Press Releases

Navitas (NASDAQ: NVTS) Surges on NVIDIA Deal – SNYR, VIGL, XAGE Lead $2 Stock Watch Now, More Inside

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Legal

Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

MLGO

NVDA

NVTS

PRSO

SNYR

VIGL

XAGE

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

BGM Group

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Goldman Sachs

Argus Research

Morgan Stanley

Screenshot 2025-03-12 at 4.47.01 PM

AMGN

BIIB

ELDN

TNXP

Tonix&#39;s TNX-1500 Shows Promise In Preventing Organ Transplant Rejections Of Either Human Or Pig Organs; Autoimmune Diseases Also A Target

Redington 2_29

BDRX

PowerShares Dynamic Financial Sector Portfolio

Comments

Sanofi

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO